DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Tobacco Products Scientific Advisory Committee; Amendment of Notice]

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Tobacco Products Scientific Advisory Committee. This meeting was announced in the Federal Register of May 19, 2010 (75 FR 28027). The amendment is being made to reflect a change in the Agenda and Procedure portions of the document. The Agenda portion is changed to cancel Topic 1 regarding dissolvable tobacco products. This portion of the meeting has been cancelled. The Procedure portion is changed to cancel Topic 2. The committee will continue discussion on topic 2.

On page 28027, in the third column, the Agenda portion of the document is changed to read as follows:

**Agenda:** On July 16, 2010, the committee will continue discussion on topic 2.

On page 28028, in the first column, the Procedure portion of the document is changed to read as follows:

**Procedure:** Oral presentations from the public (excluding the tobacco industry) will be scheduled between approximately 10 a.m. and 11 a.m. on July 16, 2010.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: June 22, 2010.

Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.

BILLING CODE 4160–01–S

SUPPLEMENTARY INFORMATION:

**II. Advance Notice of Termination**

Forivedantidurlongion on products authorized for emergency use in response to the public health emergency involving 2009 H1N1 Influenza, see the following Federal Register notices:

- For certain personal respiratory protection devices: 74 FR 38644, August 4, 2009;
- For certain antiviral drug products: 74 FR 38648, August 4, 2009; 75 FR 20430, April 19, 2010; 74 FR 56640, November 2, 2009; and 75 FR 20437, April 19, 2010; and

SUPPLEMENTARY INFORMATION:

**I. Background**

On April 26, 2009, the then Acting Secretary of the Department of Health and Human Services (DHHS) determined, under section 564(b)(1)(C) of the act (21 U.S.C. 360bbb-3(b)(1)(C)) that a public health emergency exists involving Swine Influenza A (now known as 2009 H1N1 Influenza) that affects, or has significant potential to affect, national security. The determination was renewed four times: March 26, 2010, December 28, 2009, October 1, 2009, and July 24, 2009. On March 26, 2010, the Secretary of DHHS renewed the declarations justifying the authorization for the emergency use of certain in vitro diagnostic devices, antiviral drugs, and personal respiratory protection devices. For additional background information on the declarations, see the April 2, 2010, renewal notice (75 FR 16810).

For additional background information on the products authorized for emergency use in response to the public health emergency involving 2009 H1N1 Influenza, see the following Federal Register notices:

- For certain personal respiratory protection devices: 74 FR 38644, August 4, 2009;
- For certain antiviral drug products: 74 FR 38648, August 4, 2009; 75 FR 20430, April 19, 2010; 74 FR 56640, November 2, 2009; and 75 FR 20437, April 19, 2010; and

**II. Advance Notice of Termination**

FDA is issuing this notice, under section 564(b)(4) of the act, of the termination of the declarations of emergency justifying EUAs of certain in vitro diagnostic devices, personal respiratory protection devices, and antiviral products that were issued in response to the public health emergency involving 2009 H1N1 Influenza. Under section 564(b)(3) of the act, the Commissioner of Food and Drugs provided advance notice of the termination of the declaration of emergency to the EUA requestor for each product authorized for emergency use in response to the public health emergency involving 2009 H1N1 Influenza. The June 21, 2010, letters notifying the EUA requestors of the termination of the declaration of emergency follow: